Screener
Trevi Therapeutics, Inc. TRVI Write Off Of Deferred Offering Costs
Write Off Of Deferred Offering Costs at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept trvi:WriteOffOfDeferredOfferingCosts.
The source filing: Trevi Therapeutics, Inc.’s 10-K, filed March 17, 2026.
- Filed
- Mar 17, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-110783
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Operating lease right-of-use assets | 437 | 460 |
| Depreciation and amortization | 144 | 147 |
| Accretion of available-for-sale marketable securities, net | (1,638) | (1,367) |
| Write off of deferred offering costs | 26 | — |
| Loss on disposal of property, equipment and leasehold improvements | 7 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,478) | 2,659 |
| Accrued expenses and other liabilities | (1,415) | 2,563 |
Item 16. Form 10-K Summary
FAQ
- What is Trevi Therapeutics, Inc.'s write off of deferred offering costs?
- Trevi Therapeutics, Inc. (TRVI) reported write off of deferred offering costs of $6.5K in Q4 2025.
- What does write off of deferred offering costs mean?
- This represents the non-cash expense recognized when previously capitalized costs associated with a planned or aborted financing transaction are written off. It indicates that the company has abandoned a specific capital-raising effort, requiring the immediate expensing of related legal, accounting, and filing fees. Monitoring this helps investors identify costs associated with failed financing attempts that do not provide future economic benefits.
Ask your AI about Trevi Therapeutics, Inc.'s write off of deferred offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude